Recommends using non‑sympathomimetic agents (lorcaserin, orlistat) for pharmacological weight loss in patients with cardiovascular disease. Triggers include clinician questions such as “What weight‑loss medication is safest for this patient with coronary artery disease?” or “Should I avoid phentermine in a patient with prior stroke seeking obesity treatment?”.
Installs into .claude/skills of the current project.
Are you the author of Endo Avoid Sympathomimetic Cvd?
Add the live security badge to your README. It updates with every re-scan.
[](https://www.skillsdirectory.com/skills/dromlakhani-endo-avoid-sympathomimetic-cvd)
---
name: endo-avoid-sympathomimetic-cvd
description: Recommends using non‑sympathomimetic agents (lorcaserin, orlistat) for pharmacological weight loss in patients with cardiovascular disease. Triggers include clinician questions such as “What weight‑loss medication is safest for this patient with coronary artery disease?” or “Should I avoid phentermine in a patient with prior stroke seeking obesity treatment?”.
---
# Avoid sympathomimetics in CVD for weight loss
## STEP 1 — Gather Information
Determine presence of cardiovascular disease (CAD, prior stroke, heart failure, PAD) or uncontrolled hypertension/history of heart disease; assess BMI ≥27 kg/m² with comorbidity or ≥30 kg/m²; review current medications for sympathomimetic contraindications (MAOIs, SSRIs) and obtain baseline weight, BP, heart rate.
## STEP 2 — Rule In / Rule Out
If patient has CVD (or uncontrolled hypertension/history of heart disease) and is seeking pharmacological weight loss → proceed; otherwise, standard weight‑loss medication selection applies.
## STEP 3 — Classify or Stratify
Choose lorcaserin if no concomitant serotonergic drugs (SSRI/SNRI/MAOI/triptan) and no psychiatric contraindications; otherwise select orlistat if no chronic malabsorption, cholestasis, pregnancy, or breastfeeding.
## STEP 4 — Decide
Prescribe lorcaserin 10 mg BID or orlistat 120 mg TID as adjunct to lifestyle modification; document avoidance of phentermine/diethylpropion and arrange monthly follow‑up for efficacy and safety.
## Clinical Guardrails / Mimics / Pitfalls
Do not prescribe sympathomimetics (phentermine, diethylpropion) in CVD; avoid lorcaserin with serotonergic agents due to serotonin syndrome risk; avoid orlistat in patients with chronic malabsorption, cholestasis, pregnancy, or breastfeeding; monitor BP and heart rate; ensure concurrent diet, exercise, and behavioral therapy.
## Concrete Clinical Example
A 60‑year‑old woman with prior ischemic stroke (BMI 31) asks for weight‑loss aid; she takes atorvastatin and aspirin, no antidepressants. After confirming CVD and no serotonergic meds, orlistat 120 mg TID is started; phentermine is avoided due to stroke history.
**Source:** Pharmacological Management of Obesity: An Endocrine Society Clinical Practice Guideline, Endocrine Society, 2015, DOI:10.1210/jc.2014-3415
